PDL BioPharma, Inc. Current Revenue (Deferred)

Current Revenue (Deferred) of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Revenue (Deferred) growth rates and interactive chart.


Highlights and Quick Summary

  • Current Revenue (Deferred) for the quarter ending September 29, 2016 was $11.6 Million (a 577.64% increase compared to previous quarter)
  • Year-over-year quarterly Current Revenue (Deferred) increased by 261.28%
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Revenue (Deferred) of PDL BioPharma, Inc.

Most recent Current Revenue (Deferred)of PDLI including historical data for past 10 years.

Interactive Chart of Current Revenue (Deferred) of PDL BioPharma, Inc.

PDL BioPharma, Inc. Current Revenue (Deferred) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2016 $11.61
2011 $1.71 $1.71
2010 $3.21 $3.21

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.